A Phase 1, Open-label Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Niraparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takeda
- 27 Jul 2018 Planned End Date changed from 31 Aug 2019 to 30 Sep 2018.
- 27 Jul 2018 Planned primary completion date changed from 31 Aug 2019 to 30 Sep 2018.
- 13 Apr 2018 Status changed from not yet recruiting to recruiting.